Hip Tendinitis Market Research Report – Global Forecast till 2023

Hip Tendinitis Market Research Report – Global Forecast till 2023

ID: MRFR/HC/3339-HCRR | | Region: Global | 90 pages | Half-Cooked Research Reports

Hip Tendinitis Market Research Report, By Type (Internal Snapping, External Snapping, Intra-Articular Snapping Hip), Treatment (Diagnosis, Therapy), End User (Hospitals & Clinics, Medical Research Centers, Academic Institutes) - Global Forecast Till 2023 


Market Scenario:


Hip tendonitis refer to a condition in which single or many tendons connects various muscles to the hip bone, get damaged. The hip and pelvis joints supports the body weight in an upright position. The muscles present in this region are more bulky and strong, however, tendons are prone to damage with increasing age and changing lifestyle. During the last decade, the lifestyle of the people across the globe has changed dramatically. Increasing incident of sports injuries, rising geriatric population, increasing patients population suffering from rheumatoid arthritis & diabetes, and adoption of sedentary lifestyle have led to increase the prevalence of hip tendonitis, which significantly drives the market growth. According to the US centers for diseases control, over 10% of kids and teen participating in the sports suffer from minor or major types of injuries. Additionally, increasing government support for research & development of different drugs, changing lifestyle and lack of exercise have fuelled the market growth. However, long approval time for drugs and lack of precise treatment may slow the growth of the market.


The global hip tendinitis market is expected to grow at a CAGR of 4.55% during forecast period 2017-2023. 


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers 


Figure 1:- Global hip tendinitis market share, by region

Hip Tendinitis Market


Sources: WHO, annual reports, press release, white paper, and company presentation


 


Segmentation


The global hip tendinitis market is segmented on the basis of types, treatment, and end users.


On the basis of types, the market is segmented into internal snapping hip, external snapping hip, and intra-articular snapping hip.


On the basis of treatment, the market is segmented into diagnosis and therapy. The diagnosis is further segmented into physical exam, imaging tests, and others. Imaging test is further segmented into ultrasound, magnetic resonance imaging (MRI) scans, and others. The therapy is segmented into pharmacological, non-pharmacological, shock wave or surgery, medical devices, and others. The pharmacological therapy is further segmented into OTC drugs, corticosteroids injections, platelet-rich plasma (PRP), and others. The medical devices are further segmented into mechanical band, support tape, pre-cut strips, continuous rolls, and others.


On the basis of end users, the market is segmented into hospitals & clinics, medical research centers, academic institutes, and others. 


Regional Analysis


The global hip tendinitis market is dominated by America owing to the presence of huge geriatric population and continuous increasing number of diabetic patients. As per the report published by the population reference bureau, in 2015, the number of Americans ageing over 65 were 46 million, which is expected to reach over 98 million by 2060. Furthermore, increasing number of patients suffering form rheumatoid arthritis, changing lifestyle, and huge healthcare spending have boosted the growth of the market in America. According to the American Diabetes Association, over 30.3 million Americans population were suffering from diabetes in 2015. Additionally, increasing awareness among the people regarding different types of diseases and increasing government support is likely to contribute to the growth of the market during the review period 2017-2023.


Europe accounts for the second largest hip tendinitis market, which is followed by Asia Pacific. According to the Eurostat, in 2016, 19.2% of total European population were over age 65 years. Increasing geriatric population and adoption of sports by the people may drive the market growth. Moreover, availability of funds for research, and government support for research & development are expected to fuel the market growth.


Asia Pacific is the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, and the presence of huge opportunity in the market. On the other hand, the Middle East & Africa holds the least share in the global hip tendinitis market due to presence of poor economy, especially, in African region. The Middle East holds the major share of the Middle East & African market owing to the well-developed healthcare sector and huge healthcare expenditure. 


Research Methodology

Hip Tendinitis Market-


Sources: WHO, annual reports, press release, white paper, and company presentation


 


Key players for global hip tendinitis market


Some of the key players in the global hip tendinitis market are Almatica Pharma, Inc (U.S.), AstraZeneca (U.K.), Bayer AG (Germany), Boehringer Ingelheim Pharmaceuticals, Inc (Germany), Merck & Co., Inc (U.S.), Pfizer (U.S.), Abbott (U.S.), GlaxoSmithKline plc (U.K.), Teva Pharmaceuticals (Taiwan), Lupin Pharmaceuticals, Inc. (India), Geri-Care Pharmaceuticals. (U.S.), and Perrigo Company (U.S),


 





TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Hip Tendinitis Market, by Type

6.1 Introduction

6.2 Internal Snapping Hip

Market Estimates & Forecast, 2017 – 2023

6.2.1 Vitamin D Deficiency

6.2.2 Vitamin D-Dependent Hip Tendinitis

6.3 External Snapping Hip

Market Estimates & Forecast, 2017 – 2023

6.4 Intra-Articular Snapping Hip

Market Estimates & Forecast, 2017 – 2023

6.5 Others

Chapter 7. Global Hip Tendinitis Market, by Treatment

7.1 Introduction

7.2 Diagnosis

Market Estimates & Forecast, 2017 – 2023

7.2.1 Physical Exam

7.2.2 Imaging Tests

7.2.2.1 Ultrasound

7.2.2.2 Magnetic Resonance Imaging (MRI) Scans

7.2.2.3 Others

7.2.3 Others

7.3 Therapy

Market Estimates & Forecast, 2017 – 2023

7.3.1 Pharmacological

7.3.2 Non-Pharmacological

7.3.3 Shock Wave Therapy or Surgery

7.3.4 Medical Devices

7.3.5 Others

Chapter 8 Global Hip Tendinitis Market, by End User

8.1 Introduction

8.2 Hospitals & Clinics

8.2.1 Market Estimates & Forecast, 2017 – 2023

8.3 Medical Research Centers

8.3.1 Market Estimates & Forecast, 2017 – 2023

8.4 Academic Institutes

8.4.1 Market Estimates & Forecast, 2017 – 2023

8.5 Others

Chapter 9. Global Hip Tendinitis Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Almatica Pharma, Inc

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 AstraZeneca

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Bayer AG

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Boehringer Ingelheim Pharmaceuticals, Inc

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Abbott

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Merck & Co., Inc.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 GlaxoSmithKline plc

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical industry

Chapter 13 Appendix





LIST OF TABLES

Table 1 Hip Tendinitis Industry Synopsis, 2017 – 2023

Table 2 Global Hip Tendinitis Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Global Hip Tendinitis Market by Region, 2017 – 2023, (USD Million)

Table 4 Global Hip Tendinitis Market by Types, 2017 – 2023, (USD Million)

Table 5 Global Hip Tendinitis Market by Treatment, 2017 – 2023, (USD Million)

Table 6 Global Hip Tendinitis Market by End Users, 2017 – 2023, (USD Million)

Table 7 North America Hip Tendinitis Market by Types, 2017 – 2023, (USD Million)

Table 8 North America Hip Tendinitis Market by Treatment, 2017 – 2023, (USD Million)

Table 9 North America Hip Tendinitis Market by End Users, 2017 – 2023, (USD Million)

Table 10 US Market by Types, 2017 – 2023, (USD Million)

Table 11 US Hip Tendinitis Market by Treatment, 2017 – 2023, (USD Million)

Table 12 US Hip Tendinitis Market by End Users, 2017 – 2023, (USD Million)

Table 13 Canada Market by Types, 2017 – 2023, (USD Million)

Table 14 Canada Hip Tendinitis Market by Treatment, 2017 – 2023, (USD Million)

Table 15 Canada Hip Tendinitis Market by End Users, 2017 – 2023, (USD Million)

Table 16 South America Market by Types, 2017 – 2023, (USD Million)

Table 17 South America Hip Tendinitis Market by Treatment, 2017 – 2023, (USD Million)

Table 18 South America Hip Tendinitis Market by End Users, 2017 – 2023, (USD Million)

Table 19 Europe Market by Types, 2017 – 2023, (USD Million)

Table 20 Europe Hip Tendinitis Market by Treatment, 2017 – 2023, (USD Million)

Table 21 Europe Hip Tendinitis Market by End Users, 2017 – 2023, (USD Million)

Table 22 Western Europe Market by Types, 2017 – 2023, (USD Million)

Table 23 Western Europe Hip Tendinitis Market by Treatment, 2017 – 2023, (USD Million)

Table 24 Western Europe Hip Tendinitis Market by End Users, 2017 – 2023, (USD Million)

Table 25 Eastern Europe Market by Types, 2017 – 2023, (USD Million)

Table 26 Eastern Europe Hip Tendinitis Market by Treatment, 2017 – 2023, (USD Million)

Table 27 Eastern Europe Hip Tendinitis Market by End Users, 2017 – 2023, (USD Million)

Table 28 Asia Pacific Market by Types, 2017 – 2023, (USD Million)

Table 29 Asia Pacific Hip Tendinitis Market by Treatment, 2017 – 2023, (USD Million)

Table 30 Asia Pacific Hip Tendinitis Market by End Users, 2017 – 2023, (USD Million)

Table 31 Middle East & Africa Market by Types, 2017 – 2023, (USD Million)

Table 32 Middle East & Africa Hip Tendinitis Market by Treatment, 2017 – 2023, (USD Million)

Table 33 Middle East & Africa Hip Tendinitis Market by End Users, 2017 – 2023, (USD Million)



LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Hip Tendinitis Market

Figure 3 Segmentation Market Dynamics for Global Hip Tendinitis Market

Figure 4 Global Hip Tendinitis market Share, by Type 2016

Figure 5 Global Hip Tendinitis market Share, by Treatment 2016

Figure 6 Global Hip Tendinitis Market Share, by End Users, 2016

Figure 7 Global Hip Tendinitis Market Share, by Region, 2016

Figure 8 North America Hip Tendinitis Market Share, by Country, 2016

Figure 9 Europe Hip Tendinitis Market Share, by Country, 2016

Figure 10 Asia Pacific Hip Tendinitis Market Share, by Country, 2016

Figure 11 Middle East & Africa Hip Tendinitis Market Share, by Country, 2016

Figure 12 Global Hip Tendinitis Market: Company Share Analysis, 2016 (%)

Figure 13 Almatica Pharma, Inc: Key Financials

Figure 14 Almatica Pharma, Inc: Segmental Revenue

Figure 15 Almatica Pharma, Inc: Geographical Revenue

Figure 16 AstraZeneca: Key Financials

Figure 17 AstraZeneca: Segmental Revenue

Figure 18 AstraZeneca: Geographical Revenue

Figure 19 Bayer AG: Key Financials

Figure 20 Bayer AG: Segmental Revenue

Figure 21 Bayer AG: Geographical Revenue

Figure 22 Abbott: Key Financials

Figure 23 Abbott: Segmental Revenue

Figure 24 Abbott: Geographical Revenue

Figure 25 Merck & Co., Inc.: Key Financials

Figure 26 Merck & Co., Inc.: Segmental Revenue

Figure 27 Merck & Co., Inc.: Geographical Revenue

Figure 28 GlaxoSmithKline plc: Key Financials

Figure 29 GlaxoSmithKline plc: Segmental Revenue

Figure 30 GlaxoSmithKline plc: Geographical Revenue

Figure 31 Boehringer Ingelheim Pharmaceuticals, Inc: Key Financials

Figure 32 Boehringer Ingelheim Pharmaceuticals, Inc: Segmental Revenue

Figure 33 Boehringer Ingelheim Pharmaceuticals, Inc: Geographical Revenue